CSL share price climbs as $16 billion Vifor acquisition becomes effective

CSL shares are in the green on Tuesday…

| More on:
Medical technicians wearing white medical coats conduct a test in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares climb in early trading as the company completes its Vifor Pharma acquisition 
  • The company completed its acquisition after a lengthy delay
  • CSL will hold a dedicated market briefing on 17 October, discussing Vifor Pharma’s business model and financials

The CSL Limited (ASX: CSL) share price is edging higher following the completion of the company's latest acquisition.

In earlier trading, shares in the global biotech reached $298.49, up 0.96% on yesterday's closing price. They have since fallen back to $295.70, up 0.02%.

In contrast, the S&P/ASX 200 Index (ASX: XJO) is hovering 0.03% down at 7,018 points.

CSL adds Vifor Pharma to its books

After receiving all the required regulatory clearances last week, CSL has effectively taken over Vifor Pharma AG.

The acquisition comes after CSL announced a lengthy delay back in May due to some antitrust issues.

However, with the deal now settled, CSL currently holds more than 97% of Vifor shares. At the same time, these shares will soon be removed as management will apply to delist them post-close.

The remaining 3% os stock is expected to be cancelled in accordance with Swiss takeover rules.

With the $16 billion deal completed, CSL has access to Vifor Pharma's iron deficiency, dialysis, and nephrology & rare products divisions.

CSL's upcoming results are scheduled to be released on Wednesday 17 August. Of course, they won't include any earnings from Vifor Pharma.

However, adding a global pharmaceuticals company will undoubtedly boost CSL's financial profile in the H1 FY23 period.

CEO of Vifor Pharma Abbas Hussain commented:

…I am full of confidence that Vifor Pharma will have a successful future as part of a larger, global organization. This will allow us to accelerate growth and to successfully drive multiple product launches as we continue to help even more patients around the world live better, healthier lives.

It's worth noting that CSL will hold a dedicated market briefing on 17 October. Management will discuss Vifor Pharma's growth strategy and provide insights into its product portfolio as well as its financials.

CSL share price review

Following a broader recovery on the ASX, the CSL share price climbed 2.7% in the past month.

When looking at year-to-date, CSL shares are down 0.09%.

CSL is the third-largest company on the ASX. Its market capitalisation is $142.41 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »